iXgene Inc. a biotech company based in Tokyo, is developing next-generation cell therapies based on genome-edited iPS cells. Our flagship product targets glioblastoma, one of the most challenging cancers, but our vision extends far beyond, aiming to apply this technology to various other diseases. We are building a platform that can deliver precise, scalable, and effective treatments across multiple therapeutic areas.
Company Details
- Employees
- 3
- Founded
- 2020
- Address
- Yotsuya, Shinjuku-Ku,tokyo,japan
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.ixgene.inc/en/
- HQ
- Shinjuku-ku, Tokyo
Ixgene Inc. Questions
Ixgene Inc.'s website is https://www.ixgene.inc/en/
Ixgene Inc.'s LinkedIn profile is https://jp.linkedin.com/company/ixgene-inc
Ixgene Inc. has
3 employees.
View email and phone details for 3
employees at Ixgene Inc..
Ixgene Inc.'s industry is
Biotechnology Research
Ixgene Inc.'s top competitors are
Tilt Biotherapeutics Ltd,
Immunokey,
Limula,
T-Knife Therapeutics,
Strike Pharma Ab,
Alterbio,
Molmir, Inc,
Chimeron Bio,
Editforce Inc.,
Inndura Therapeutics.
Ixgene Inc.'s categories are Biotechnology Research
Ixgene Inc.'s founding year is 2020
